PM534 Administered Intravenously to Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
The goals of this trial are to identify the dose limiting toxicities, to determine the
maximum tolerated dose and the recommended dose of PM534 in patients with advanced solid
tumors. All Patients will receive PM534 via intravenous.